Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study

Dataset

2017
Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study
Pollack, C. V., Bernstein, R. A., Dubiel, R., Reilly, P., Gruenenfelder, F., Huisman, M. V., Kam, C. W., Kleine, E., Levy, J. H., Sellke, F. W., Steiner, T., Ustyugova, A. & Weitz, J. I., May 4 2017, In: Journal of Medical Economics. 20, 5, p. 435-442 8 p.
Research output: Contribution to journal › Article › peer-review
8 Scopus citations

Research output